Table 3.

Summary of best objective response (for calculation of duration of percent response)

Best objective response	Number (%) of patients
	Fulvestrant 500 mg (n = 362)	Fulvestrant 250 mg (n = 374)
CR	4 (1.1)	1 (0.3)
PR	29 (8.0)	37 (9.9)
SD ≥24 weeks	132 (36.5)	110 (29.4)
SD <24 weeks	47 (13.0)	52 (13.9)
PD	140 (38.7)	167 (44.7)
NE	10 (2.8)	7 (1.9)

Best response derived according to modified RECIST

CR complete response, NE not evaluable, PD progressive disease, PR partial response, RECIST Response Evaluation Criteria In Solid Tumors, SD stable disease